- Home
- SVII vs ABEO Comparison
SVII vs ABEO Comparison
Compare SVII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- ABEO
- Stock Information
- Founded
- SVII 2021
- ABEO 1974
- Country
- SVII United States
- ABEO United States
- Employees
- SVII N/A
- ABEO N/A
- Industry
- SVII Blank Checks
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- ABEO Health Care
- Exchange
- SVII Nasdaq
- ABEO Nasdaq
- Market Cap
- SVII 116.6M
- ABEO 256.9M
- IPO Year
- SVII 2022
- ABEO 1980
- Fundamental
- Price
- SVII $11.87
- ABEO $5.95
- Analyst Decision
- SVII
- ABEO Strong Buy
- Analyst Count
- SVII 0
- ABEO 6
- Target Price
- SVII N/A
- ABEO $18.00
- AVG Volume (30 Days)
- SVII 5.3K
- ABEO 1.1M
- Earning Date
- SVII 01-01-0001
- ABEO 08-11-2025
- Dividend Yield
- SVII N/A
- ABEO N/A
- EPS Growth
- SVII N/A
- ABEO N/A
- EPS
- SVII 0.25
- ABEO N/A
- Revenue
- SVII N/A
- ABEO N/A
- Revenue This Year
- SVII N/A
- ABEO N/A
- Revenue Next Year
- SVII N/A
- ABEO $322.37
- P/E Ratio
- SVII $47.86
- ABEO N/A
- Revenue Growth
- SVII N/A
- ABEO N/A
- 52 Week Low
- SVII $11.06
- ABEO $3.93
- 52 Week High
- SVII $11.90
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- SVII 63.77
- ABEO 51.37
- Support Level
- SVII $11.64
- ABEO $5.66
- Resistance Level
- SVII $11.78
- ABEO $5.99
- Average True Range (ATR)
- SVII 0.09
- ABEO 0.24
- MACD
- SVII 0.02
- ABEO 0.01
- Stochastic Oscillator
- SVII 100.00
- ABEO 74.19
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.